Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07146230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Study acronym: SPRINT 2
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 2026 to Sep 2026
    • Primary completion pushed from Dec 2027 to Apr 2028
    • Study completion pushed from Oct 2028 to Feb 2029
    v5
  2. Start date: Mar 1, 2026 to May 2026
    • Primary completion date: Oct 2027 to Dec 2027
    • Study completion date: Aug 2028 to Oct 2028
    v4
  3. Start date: Sep 2025 to Mar 1, 2026
    • Primary completion date: Apr 2027 to Oct 2027
    • Study completion date: Feb 2028 to Aug 2028
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two dual-agent immunotherapy regimens: durvalumab + monalizumab versus durvalumab + oleclumab.
Trial Details
NCT Number NCT07146230
Lead Sponsor Montefiore Medical Center
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov